Abstract 81P
Background
Despite immune-checkpoint inhibitors (ICIs) transforming outcomes of melanoma patients, a vast number remain unresponsive to treatment. Baseline-derived host-related inflammatory ratios such as neutrophil-lymphocyte ratio (NLR), platelet-lymphocyte ratio (PLR) and monocyte-lymphocyte ratio (MLR) are easily accessible biomarkers that can depict the balance between myeloid-derived protumour inflammation and lymphocyte-derived antitumour response. Our analysis aims to assess the predictive value of baseline inflammatory ratios on the outcome of melanoma patients treated with mono-ICIs.
Methods
We conducted a multicentric retrospective analysis that included 112 advanced melanoma patients treated with mono-ICI (Pembrolizumab or Nivolumab) at three Centers in Serbia and Bosnia & Herzegovina. Data were extracted from the European Melanoma Registry (EuMelaReg). ROC curves with Youdens J-statistic were used to determine optimal cut-off-values (NLR: 3.35, PLR: 165.5, MLR: 165.5). The p-values regarding Progression-free survival (PFS and overall survival (OS) were calculated using log-rank (p<0.05; CI 95%).
Results
Each of the inflammatory ratios separately showed poorer prognosis in high-value subgroup in terms of shorter PFS (NLR: 3.55 vs 14.01- p<0.0001; PLR: 3.85 vs 11.48- p=0.0011; MLR: 5.16 vs 11.48- p=0.0171) and OS (NLR: 5.69 vs 23.59- p<0.0001; PLR: 6.12 vs 23.59- p<0.0001; MLR: 8.42 vs 21.78- p=0.0007). In group analysis, patients with all three ratios elevated were compared with patients with at least one low ratio. Shorter PFS (2.86 vs 10.56; p<0.0001) and OS (6.78 vs 21.45; p<0.0001) were also observed in the all-high subgroup. Patients with high-value ratios were younger (p=0.0162). No difference was observed in terms of gender (p=0.99), BRAF mutation status (p=0.53), the occurrence of immune-related adverse events (p=0.34) or LDH levels (p=0.16).
Conclusions
Inflammatory ratios are promising and accessible biomarkers that solely, or combined could be incorporated into clinical practice delineating patients who will benefit the most from mono-ICI and those who would need additional agents or a different therapeutic approach.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
216P - Spatial transcriptomics reveals tumor-microenvironment heterogeneity of breast cancer
Presenter: Hyun Lee
Session: Poster Display session
Resources:
Abstract
217P - Tumor-derived CCL15 regulates RNA m6A methylation in cancer-associated fibroblasts to promote hepatocellular carcinoma growth
Presenter: Yueguo Li
Session: Poster Display session
Resources:
Abstract
218P - A novel tumor adenosine signature to guide indication selection for adenosine pathway inhibitors
Presenter: Sophie Dekoninck
Session: Poster Display session
Resources:
Abstract
219P - Radiotherapy, in conjunction with a PI3Kd/? inhibitor, enhances effector CD8+ T cell-mediated anti-tumor immune responses and the memory function of T cells within the tumor microenvironment by stimulating innate immunity
Presenter: Ye hyun Kim
Session: Poster Display session
Resources:
Abstract
220P - Correlation research between oral flora diversity and radiation-induced stomatitis after postoperative radiotherapy for oral squamous cell carcinoma
Presenter: Qin Zheng
Session: Poster Display session
Resources:
Abstract
221P - Chemoradiotherapy induced adaptive anti-tumor T cell immunity in patients with non-small cell lung cancer
Presenter: Yaoyao Xie
Session: Poster Display session
Resources:
Abstract
222P - Features of epithelial-to-mesenchymal transition (EMT) and humoral immune response in ulcerated acral melanoma: A transcriptomic and spatial proteomic analysis.
Presenter: Estefania Vazquez
Session: Poster Display session
Resources:
Abstract
223P - Frequency of the number of myeloid-derived suppressor cells in patients with lung cancer according to T stage
Presenter: Jelena Vukovic
Session: Poster Display session
Resources:
Abstract
224P - Immunological Dynamics in Triple-Negative Breast Cancer: Peripheral Immune Responses to Neoadjuvant Therapy
Presenter: Rita Santos
Session: Poster Display session
Resources:
Abstract
225P - Assessment of immune cell populations in the peripheral blood of metastatic prostate cancer
Presenter: Vanessa Patel
Session: Poster Display session
Resources:
Abstract